Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...
The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...
Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...
On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...
However, new research by scientists working at the Institut Pasteur’s Microbial Paleogenomics Unit finds two previously ...
The Print on MSN
Doctors still treat heart disease with trial and error. This start-up wants to change that
India-specific database of Coronary Artery Diseases will help identify if a person has a risk factor of developing heart ...
The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.
Eli Lilly partners with Nvidia to build the pharma industry’s most powerful AI supercomputer, aiming to speed up drug ...
Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback